Dr Stephen Franklin, Chief Executive Officer of Evgen Pharma LON:EVG, said: “We are very pleased to have progressed our SFX-01 product candidate into two phase II clinical trials: in breast cancer and in subarachnoid haemorrhage. This is a significant step for Evgen Pharma, and for sulforaphane-based science.
“The increasing body of evidence that sulforaphane has broad therapeutic potential, combined with our expanding IP portfolio over technology for manufacturing sulforaphane-based drugs at commercial scale, gives Evgen Pharma confidence in its clinical strategy.”
Evgen Pharma plc (AIM:EVG), the clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces its final results for the year ended 31 March 2017.
— First patient dosed in the ongoing SAS (SFX-01 After Subarachnoid Haemorrhage) Phase II clinical study
— First patient dosed in the ongoing STEM (SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer) Phase IIa clinical study
— Orphan drug designation granted by the US Food & Drug Administration for the use of stabilised sulforaphane in subarachnoid haemorrhage (“SAH”)
— Positive data from preclinical studies of SFX-01 in various models of the relapsing remitting form of multiple sclerosis (“MS”) presented at leading MS conference
— Additional patents granted over manufacturing processes for SFX-01
— Recently, and subsequent to the period, the first patient to enter the STEM trial has now been accepted onto the compassionate use programme, having demonstrated no disease progression during the trial
— Financial performance in line with expectations:
- Total comprehensive loss of GBP3.1m (2016: loss of GBP3.1m)
– Net cash outflow (before short-term investment movements) of GBP3.3m (2016: inflow of GBP6.9m)
– Cash and short term investments and cash on deposit at 31 March 2017 of GBP3.9m (31 March 2016: GBP7.1m)
A meeting for analysts will be held at 11.00am this morning, 13 June 2017, at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. Please contact Buchanan on 020 7466 5000 for further information.